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INTRODUCTION
It has been reported that fenofibrate prevents weight gain
(1) or body adiposity (2) in a variety of animal models (3-5).
The mechanism that explains the effects of the peroxisome
proliferator-activated receptor (PPAR)  activator has been
attributed to increased fat catabolism in the liver primarily
resulting from the induction of target enzymes involved in
hepatic lipid metabolism (6, 7). According to a recent report
(8), the effect of fenofibrate on adipose tissue metabolism may
also contribute to decreasing adipose tissue. We have also
previously shown that fenofibrate therapy reduced abdomi-
nal and skeletal adiposity and enhanced hepatic expression
of fatty acid translocase (FAT)/CD36 and carnitine palmitoyl-
transferase (CPT)-I mRNA (9).
The effect on food intake of the PPAR  activator has been
inconsistent. Some have reported that reduced adiposity with
fenofibrate was associated with the reduction of food intake
in obese diabetic rats (9), high-fat-fed rats (10) and diabetic
mice (11); however, there have been several reports showing
that PPAR  did not change with food intake.
PPAR  has also been suggested to regulate energy home-
ostasis. Three distinct uncoupling protein (UCP) isoforms,
UCP-1, UCP-2, and UCP-3, have been implicated as medi-
ators of thermogenesis. Brown adipose tissue (BAT) has been
known to be an important site of thermogenesis in rodents.
UCP-1, which is expressed exclusively in BAT, expression
levels are reduced in several rodent models of obesity (12).
UCP-1 functions to uncouple oxidative metabolism from
ATP synthesis, resulting in the generation of heat (13). There
is strong evidence that increased fat metabolism is associat-
ed with increased expression of UCP-2 and UCP-3 (14, 15).
In addition, PPAR  as well as  activators have been suggest-
ed to induce the expression of UCP-2 in hepatocytes (16) and
UCP-3 in adipose tissues (17, 18) and skeletal muscles (19).
Treatment of db/db mice with WY-14643, one PPAR  acti-
vator, did not affect expression of UCP-1, -2, or UCP-3 in
BAT (20). 
In a previous study, we suggested that the relationship
between increased  -oxidation and anti-adiposity resulted
in ‘‘the burning fuel effect’’ (9). We thought that fenofibrate
increased fatty acid oxidation in hepatic mitochondria and
Mi-Kyoung Park, Hye-Jeong Lee*, 
Sook-Hee Hong
� , Sun-Seob Choi
� , 
Young Hyun Yoo
�, Kyung Il Lee
‖, 
Duk Kyu Kim
Departments of Internal Medicine, Pharmacology*,
Pathology
� , Radiology
� , Anatomy
�, Medical Science
Research Institute, Dong-A University College of
Medicine, Busan; Department of Internal Medicine
‖,
Baptist Hospital, Busan, Korea
Address for correspondence
Duk Kyu Kim, M.D.
Department of Internal Medicine, Medical Science
Research Institute, Dong-A University College of
Medicine, 1 3-ga Dongdaesin-dong, Seo-gu, Busan
602-714, Korea
Tel : +82.51-240-2972, Fax : +82.51-242-5852
E-mail : dkkim@dau.ac.kr
*This work was supported by the Dong-A University
Medical Center Research Fund and Dong-A University
Research Fund in 2003 and by Korea Research 
Foundation Grant (KRF 2004-005-E0030).
235
J Korean Med Sci 2007; 22: 235-41
ISSN 1011-8934
Copyright � The Korean Academy
of Medical Sciences
The Increase in Hepatic Uncoupling by Fenofibrate Contributes to a
Decrease in Adipose Tissue in Obese Rats
Fenofibrate is a drug that has been suggested to inhibit weight gain by increasing
the catabolism of fatty acid in the hepatic mitochondria. We hypothesized that feno-
fibrate induces an increase in energy expenditure in the hepatic mitochondria, which
results in the reduction of adipose tissue. In this study we measured hepatic uncou-
pling protein (UCP)-2, -3, core temperatures and abdominal fat composition with
MRI in Otsuka Long-Evans Tokushima Fatty rats. The fenofibrate group (n=7) was
fed fenofibrate (320 mg/kg) mixed chow. The control group (n=7) was fed chow only.
The body weight (531.6± ±7.6 g) of the fenofibrate group was significantly lower than
that (744.3± ±14.9 g) of the control group (p<0.005). The areas of visceral and sub-
cutaneous fat in the fenofibrate group (11.0± ±0.9 cm
2, 4.2± ±0.3 cm
2) were signifi-
cantly less than those in the control group (21.0± ±0.7 cm
2, 7.4± ±0.4 cm
2) (p=0.046,
respectively). The esophageal and rectal temperatures of the fenofibrate group (37.7
± ±0.1°C, 33.1± ±0.2°C) were significantly higher than those of the control group (37.3
± ±0.1°C, 32.2± ±0.1°C) (p=0.025, p=0.005). There was de novo expression of UCP-
3 in the liver of the fenofibrate group. These data suggest that increased energy
dissipation, via hepatic UCP-3 by fenofibrate, contribute to decreased weight gain
in obese rats.
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consumed fat fuels, which resulted in increasing hepatic influx
of fatty acid from fat depots especially from visceral fat. How-
ever, it was unclear how increased  -oxidation by chronic
treatment with the PPAR  activator could increase energy
expenditure rather than energy generation in the liver.
In this study, we hypothesized that chronic fenofibrate treat-
ment might increase energy expenditure by induction of an
uncoupling mechanism in the hepatic and/or skeletal mus-
cular mitochondria, which may contribute to a decrease in
body adiposity. 
MATERIALS AND METHODS
Animals and diet
Otsuka Long-Evans Tokushima Fatty (OLETF) rats four
weeks of age, a type 2 diabetes animal model (n=14) were
kindly donated from Otsuka Pharmaceuticals (Tokushima,
Japan); diabetes mellitus did not develop in any of these rats
until 61 weeks of age for unknown reasons. They were fed
with the standard rat diet and tap water ad libitum until 10
weeks of age. At this age, all of the OLETF rats were ran-
domly divided into two groups. The average body weight
of rats in the two groups was not significantly different. The
one, the fenofibrate group (n=7), was fed with powdered diet,
mixed with micronized fenofibrate (0.5% w/w, 320 mg/kg/
day) and the other, the control group (n=7), was fed with
powdered diet only. The fenofibrate group was fed freely. For
paired-feeding, the total food intake of the fenofibrate group
was monitored every two days and the same amount of food
intake was provided to the control group. Body weights of
each rat were monitored weekly. All the rats were cared and
handled during the entire period of the experiment by the
Guidelines for Animal Experiments developed by The Korean
Academy of Medical Sciences.
Measurement of blood glucose and ketone levels
At 60 weeks of age, after 12 hr of fasting, all rats inhaled
ether after which we sampled blood from the tail vein for
measurement of glucose and  -ketone. Whole blood glu-
cose and  -ketone levels were measured with a MediSense
Optium using blood glucose strips and  -ketone test strips
(Abbott Laboratories, MediSense Products, Bedford, MA,
U.S.A.).
Measurement of plasma lipid and insulin levels
At 61 weeks of age, after 12 hr fasting, all rats inhaled ether
and were injected with ketamine (200 mg/kg) into the peri-
toneum. After the anesthesia was administered, we sacrificed
all of the rats; blood samples were drawn for measurements
of the plasma levels of free fatty acid, total cholesterol, triglyc-
eride, high-density lipoprotein cholesterol (HDL-C) and in-
sulin from the inferior vena cava. The blood samples were
collected in 4.5% EDTA-treated bottles and stored in ice
bottles at -20℃. The plasma levels of total cholesterol (Infin-
ity Cholesterol Reagent, Sigma Diagnostics, St. Louis, MO,
U.S.A.), triglyceride (Infinity Triglycerides Reagent, Sigma
Diagnostics, St. Louis, MO, U.S.A.) and HDL-C (EZ HDL
Cholesterol, Sigma Diagnostics, St. Louis, MO, U.S.A.) were
measured by the enzyme method. The plasma level of free
fatty acid (FFA) was measured by the ACS-ACOD enzyme
method (NEFA ZYME-S, Aiken, Japan). Plasma insulin levels
were analyzed with a rat insulin radioimmunoassay kit (Linco
Research Inc, St. Charles, MO, U.S.A.). 
Measurement of fat amount by MRI
At 61 weeks of age, a day after body temperature measure-
ment, six rats were selected randomly for MRI study. All rats
were anesthetized as in the method described above. The rats
(n=3 in each group) were placed in supine position with a
V shaped hand-made fixing device to secure a constant posi-
tion with flexion of the hip joint to prevent stretching of the
thigh muscle. The imaging was performed on a 1.5 Tesla MRI
machine (Magnetom Vision, Siemens, Erlangen, Germany)
with a loop coil at the mid-abdominal level. Coronal and
axial scans were obtained. First, the coronal scout view was
obtained and then the axial scan was performed at the level
just inferior to the lower pole of left kidney. The image param-
eters of T1 weighted images were 350/30 msec of TR/TE
(time to repetition/time to echo), 8.8×10 cm of field of view,
190×256 for matrix number and three times for acquisition.
In the scanned images, the areas of the region of interest pre-
senting visceral and subcutaneous fat tissue were calculated
automatically with an installed program (Vision VB33D) in
the MRI. 
Reverse Transcriptase-Polymerase Chain Reaction (RT-
PCR) analysis
At 61 weeks of age, we obtained tissue samples for RT-
PCR. Total RNA was isolated using TRIzol (Life Technolo-
gies, U.S.A.). Complementary DNA was synthesized from
RNA samples by enhanced AMV reverse transcriptase. An
aliquot of the reverse transcription reaction was then used
for subsequent PCR amplification with specific primers. The
sequences of the sense and antisense primers used for ampli-
fication were as follows: UCP-2, 5′ -AACAGTTCTACAC-
CAAGGGC-3′ and 5′ -AGCATGGTAAGGGCACAGTG-
3′ ; UCP-3, 5′ -GGAGCCATGGCAGTGACCTGT-3′ and
5′ -TGTGATGTTGGGCCAAGTCCC-3′ ; -actin,  5′ -GT-
GGTGGTGAAGCTGTAGCC-3′ and 5′ -GAGACCTTC-
AACACCCC-3′ . PCR was performed in the Gene Amp PCR
system 2,400 (Perkin-Elmer, U.S.A.). After initial denatu-
ration for 5 min at 94℃, PCR was performed for 30 cyclesInduction of Hepatic UCP-3 by Fenofibrate and Anti-adiposity 237
for all samples. Each cycle consisted of denaturation at 94℃
for 1 min, primer annealing at 56℃ for 1 min, and primer
extension at 72℃ for 1 min. A final 5 min extension step at
72℃ was included. Amplification of each gene yielded a
single band of the expected size (UCP-2, 471 bp; UCP-3,
179 bp; beta-actin 763 bp). Preliminary experiments were
carried out with various amounts of cDNA to determine
nonsaturating conditions of PCR amplification for all of the
genes studied. Therefore, under these conditions, the RT-PCR
method used in this study permitted relative quantification
of mRNA. The illuminated bands were quantified by Image
Gauge (Fujifilm, Tokyo, Japan). The results of the expression
of specific mRNAs were presented relative to the expression
of the control gene.
Western blot analysis
Frozen hepatic tissue were homogenized in a buffer con-
taining 50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA,
25 mM sodium fluoride, 0.2% Triton X-100, 0.3% NP 40
and protease inhibitors (aprotinin 1  g/mL, leupeptin 1  g/
mL PMSF 10 mM/L). The homogenates were centrifuged
and the supernatant was decanted and saved on ice. Protein
concentrations were measured using the BCA kit (Sigma
Chemical Co., St. Louis, MO, U.S.A.). The proteins were
separated on a 12% SDS-polyacrylamide gel and transferred
electrophoretically onto a nitrocellulose membrane (Amer-
sham, Arlington Heights, IL, U.S.A.) using a mini electro-
blotter (BioRad Laboratories, Hecules, CA, U.S.A.). The nitro-
cellulose membrane was blocked in Tris-buffered saline con-
taining 0.1% Tween and 5% non-fat milk and then incubat-
ed over night at 4℃ in anti-rat UCP3 polyclonal antibody
(Fitzgerald Industries International, Inc, MA, U.S.A.). After
washing in Tris-buffered saline containing 0.1% Tween, blots
was incubated with an anti-rabbit IgG antibody conjugated
to horseradish peroxidase (Amersham, Arlington Heights,
IL, U.S.A.). Immunoreactive bands were visualized with ECL
PlusTM Western Blotting Detection Reagents (Amersham,
Arlington Heights, IL, U.S.A.).  -actin (42 kDa; Sigma
Chemical Co., St. Louis, MO, U.S.A.) was used as the inter-
nal control.
Measurement of core temperature
At 61 weeks of age, all rats were anesthetized with ketamine
(200 mg/kg, intraperitoneal injection), and the thermometer
probe (Temperature controller, DX4-PSSNR, KSC 1614,
HANYOUNG, Seoul, Korea) was placed into the esophageal
and rectal canals. We evaluated both temperatures twice on
separate days under the same conditions. 
Statistical analysis
All results are presented as means±SEM. Significant dif-
ferences in the data between the groups were analyzed by the
Mann-Whitney U test. We used the statistical programs in
SPSS 9.0 version for Windows. In all cases, a pvalue estimat-
ed less than 0.05 was considered significant.
RESULTS
Change of body weight 
As mentioned previously, the fenofibrate group was fed freely
and the control group was fed the same amount as the fenofi-
brate group. The mean amount of daily food consumption
in both groups was 26.1±2.8 g. The body weights in both
groups increased continuously until the end of experiment.
The mean body weight of the control group was 744.3±
14.9 g and that in the fenofibrate group was 531.6±7.6 g
at 61 weeks of age. The average weight of the fenofibrate
group was significantly less than that of the control group
from 14 through 61 weeks (p<0.005, Fig. 1A).
The weight gain during the experimental period in the
fenofibrate group (326.6±8.5 g, 160.2±7.8%) was sig-
nificantly decreased compared to the control group (543.7±
11.0 g, 271.2±12.3%) (p=0.002, Fig. 1B).
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Fig. 1. (A) Chronological changes of body weight in the two groups. The body weight of the rat in both groups increased continuously dur-
ing the entire period of the experiment. The average body weight in the fenofibrate group (closed circle) was significantly less than that
in the control group (open circle) during 14-61 weeks (p<0.005). (B) Percent change of body (delta) weight in the two groups. The fenofi-
brate group showed significantly less weight gain than the control group during the experimental period (p=0.002).
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Blood glucose, insulin, lipid and ketone levels
The whole blood glucose level in the fenofibrate group
(7.98±0.97 mM/L) was slightly decreased compared to that
of the control group (11.06±2.48 mM/L), but the difference
was not significant. The plasma insulin levels were not sig-
nificantly different between the two groups (Table 1). As has
been already noted, diabetes did not develop in this strain. 
To verify the effects of fenofibrate treatment, we measured
plasma lipid profiles. At the end of the experiment, the plasma
levels of FFA, triglyceride and total cholesterol in the fenofi-
brate group were significantly decreased compared with those
in the control group (p<0.05). The HDL cholesterol levels
showed no significant difference between the two groups.
The whole blood  -ketone of the fenofibrate group (0.60±
0.07 mM/L) was slightly increased compared to that of the
control group (0.57±0.06 mM/L) but this finding was not
significant (Table 1).
Abdominal fat size
We measured abdominal fat composition with MRI. The
areas with visceral and subcutaneous fat were calculated auto-
matically. As shown in Fig. 2, the visceral fat area, represent-
ing V, was 21.0±0.7 cm2 and the subcutaneous fat area, rep-
resenting S, was 7.4±0.4 cm2 in the control group (Fig. 2A).
The visceral fat area and the subcutaneous fat area were 11.0
The data represent the mean±SEM of 7 animals per group. Mann-Whit-
ney U test. NS, not significant.
Control Fenofibrate p value
Glucose (mM/L) 11.06±2.48 7.98±0.97 NS
Insulin (pM/L) 312.08±64.74 174.30±28.22 NS
Free fatty acid (mM/L) 0.37±0.02 0.14±0.02 <0.05
Triglyceride (mM/L) 3.03±0.51 0.75±0.19 <0.05
Total cholesterol (mM/L) 3.94±0.20 2.07±0.11 <0.05
HDL-C (mM/L) 1.12±0.24 1.26±0.21 NS
-Ketone (mM/L) 0.57±0.06 0.60±0.07 NS
Table 1. Blood glucose, insulin, lipids and ketone levels in both
groups
Fig. 2. Comparison of the fat tissue areas between control and fenofibrate treated groups. Fat tissue areas in T1 weighted images just
beneath the level of the lower pole of the left kidney, were measured automatically. (A) Coronal scan image. This presents the level (-----)
for the axial scanning. (B, C) Axial image of the fenofibrate group and of the control group, respectively. The visceral (V) and subcutaneous
(S) fat areas were significantly decreased in the fenofibrate group compared with the control group, respectively (p<0.05, Table 2).
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Fig. 3. (A) Expression of UCP-2 and UCP-3 mRNA in the liver. (B) Expression of UCP-2 and UCP-3 in muscle. UCP-2 mRNA was well exp-
ressed in the liver from both groups. However, there was distinctive de novo expression of UCP-3 in the liver of the fenofibrate group. UCP-
2 and UCP-3 were well expressed in skeletal muscle in both groups. There were no significant changes in the levels of muscular UCP-2
and UCP-3 mRNA in both groups.
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16±0.9 cm2 and 4.2±0.3 cm2, respectively, in the fenofibrate
group (Fig. 2B). Therefore, the fat areas were significantly
decreased in the fenofibrate group compared to the control
group (p=0.046) (Table 2).
The expression of UCP-2 and UPC-3 in liver and muscle
To examine whether UCP-2 and UCP-3 in liver and mus-
cle were unregulated by fenofibrate, we measured the expres-
sion of UCP-2 and UCP-3 mRNA by RT-PCR. As shown
in Fig. 3, the expression of UPC-2 mRNA in liver and mus-
cle did not show a sighificant difference between the two
groups. The expression of UCP-3 mRNA in muscle showed
no difference between the groups. However, hepatic UCP-3
mRNA appeared to be newly synthesized with fenofibrate
treatment (Fig. 3A).
De novo expression of UCP-3 mRNA levels in the liver
were reflected by the parallel effects on UCP-3 protein con-
tent, as measured by Western blot analysis (Fig. 4). In the
fenofibrate treatment group, UCP-3 protein was detected,
but not in the control group. 
Body core temperature 
If hepatic UCP-3 works as an uncoupling protein, the body
core temperature may be increased. We measured body core
temperatures to confirm this hypothesis. The esophageal tem-
peratures were significantly higher in the fenofibrate group
compared to those in the control group (37.7±0.1 vs. 37.3±
0.1, p=0.025). The rectal temperatures were also significantly
higher in the fenofibrate group compared to the control group
(33.1±0.2℃vs. 32.2±0.1℃, p=0.005) (Fig. 5).
DISCUSSION
We found that chronic fenofibrate treatment resulted in
decreased body weight and abdominal adiposity. These effects
of fenofibrate treatment were not associated with a dietary
factor because the amount of oral intake was the same in both
groups studied. 
We also found that the core temperatures of the fenofibrate
treated rats were significantly increased. This demonstrates
that a large amount of energy was dissipated as heat especially
from the liver. This heat may have resulted from uncoupling
by UCP-2 as well as UCP-1 and UCP-3, if they are expressed
in the liver.
In this study we observed that fenofibrate did not signifi-
cantly increase the expression of UCP-2 mRNA and UCP-
3 mRNA in skeletal muscle, but induced newly expressed
UCP-3 mRNA in hepatic tissues. These data suggest that
the major target organ for fenofibrate treatment is the liver,
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Fig. 5. Comparison of body core temperatures between control and fenofibrate groups. (A) Esophageal temperature, (B) rectal tempera-
ture. Flexible thermometer probes were placed into the esophageal and rectal canals. Digital body temperatures were monitored and
measured. Both esophageal and rectal temperatures were significantly increased in the fenofibrate group compared to the control group,
respectively (p<0.05).
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The data represent the mean±SEM of 3 animals per group. Mann-Whit-
ney Utest. 
Control Fenofibrate p value
Visceral fat (V) area (cm
2) 21.0±0.7 11.0±0.9 <0.05
Subcutaneous fat (S)  7.4±0.4 4.2±0.3 <0.05
area (cm
2)
Table 2. The comparison of fat tissue areas between control and
fenofibrate groups
Fig. 4. Representative Western blot of hepatic protein lysates prob-
ed with anti-UCP-3 antibody in the liver. In the fenofibrate treatment
group, the UCP-3 protein was detected, but it was not detected
in the control group. 
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The exact physiologic role of UCP-3 in the liver is uncer-
tain. There are two theories suggested on the function of
UCPs. One is the uncoupler theory and the other is the ex-
porter theory. The uncoupler theory can explain the anti-adi-
posity effect of fenofibrate. Fenofibrate increases  -oxidation
of fatty acid, which leads to the production of acetyl CoA.
Acetyl CoA may enter the TCA cycle, where it is converted
into citrate by citrate synthase. During  -oxidation of fatty
acids and the TCA cycle, high-energy electrons in the form
of nicotinamide adenine dinucleotide (reduced from) (NADH)
or flavin adenine dinucleotide (reduced from) (FADH) are gen-
erated. These electrons released in the re-oxidation of NADH
and FADH2 flow through the electron-transport chain to
generate a proton gradient across the inner mitochondrial
membrane. When these protons flow through uncoupling
proteins (such as UCP-3), their energy is converted into heat
and then dissipated (21). 
The function of UCP-3 as an exporter has also been postu-
lated; this protein could be an exporter of fatty acid anions
from the mitochondrial matrix under conditions of increased
fatty acid oxidation (21). This hypothesis proposes that excess
acyl CoA, within the mitochondria, is hydrolyzed by a mito-
chondrial acyl CoA thioesterase, yielding a fatty acid anion
and coenzyme A (CoASH). The fatty acid anion is exported
to the cytosol by being carried across the inner mitochon-
drial membrane by UCP-3. The exported fatty acid anion
returns to the pool of fatty acid anions in the cytosol and is
recycled by ATP consumption (22). Thus the energy con-
sumption, via UCP proteins in the liver, can be explained
by the uncoupler or exporter theory, though the efficiency
of energy consumption would be different for each of them.
A recent report by Linn et al. (23) showed that fenofibrate
induced de novo expression of UCP-3 in the liver of Winstar
rats. They suggested that such de novo expression was asso-
ciated with enhanced fatty acid metabolism by fenofibrate.
Because UCP genes contain functional PPAR-responsive
elements (24), they may be target genes for the PPAR acti-
vator (25).
The increased core (esophageal and rectal) temperatures
suggest that fenofibrate treated rats may increase heat pro-
duction or metabolic rate. If the major role of hepatic UCP-
3 is an uncoupler, this de novo expression of UCP-3 by fenofi-
brate treatment may be indirect evidence that fenofibrate
can increase heat production or energy expenditure.
The increased body core temperature and hepatic UCP-3
expression induced by fenofibrate supports the hypothesis
that hepatic UCP-3 works as an uncoupler protein rather
than an exporter protein. However, we did not provide direct
evidence that UCP-3 works as an uncoupler. This unsolved
topic may be resolved by measuring state-4 respiration and
membrane potentials of isolated hepatic mitochondria, which
would be diagnostic of mitochondrial uncoupling activity.
There may be no reason to accumulate adipose tissue in
subcutaneous regions under conditions of increased core tem-
perature; this is because the major function of subcutaneous
fat is to insulate the body by maintaining heat at a constant
body temperature. Thus the loss of subcutaneous fat mass
might be enhanced by adaptive responses to increased core
temperature.
In conclusion, fenofibrate decreases visceral and then sub-
cutaneous fat mass. A possible hepatic mechanism for dec-
reasing visceral adiposity is that fenofibrate increases hepatic
energy dissipation via de novo expression of UCP-3 in mito-
chondria. The decreased subcutaneous fat mass results from
adaptive mechanisms in response to increased core tempera-
ture induced by increased energy combustion. 
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